These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1016 related articles for article (PubMed ID: 28446057)
21. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma. Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553 [TBL] [Abstract][Full Text] [Related]
22. Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival. White MG; Cipriani NA; Abdulrasool L; Kaplan S; Aschebrook-Kilfoy B; Angelos P; Kaplan EL; Grogan RH; Onel K Thyroid; 2016 Aug; 26(8):1053-60. PubMed ID: 27279587 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797 [TBL] [Abstract][Full Text] [Related]
24. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study. Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902 [TBL] [Abstract][Full Text] [Related]
25. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672 [TBL] [Abstract][Full Text] [Related]
26. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Lee N; Tuttle M Endocr Relat Cancer; 2006 Dec; 13(4):971-7. PubMed ID: 17158749 [TBL] [Abstract][Full Text] [Related]
27. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER. Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128 [TBL] [Abstract][Full Text] [Related]
28. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma. Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568 [TBL] [Abstract][Full Text] [Related]
29. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA. Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694 [TBL] [Abstract][Full Text] [Related]
30. The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM; Wheeler MH; Clark OH Curr Opin Gen Surg; 1994; ():53-9. PubMed ID: 7584009 [TBL] [Abstract][Full Text] [Related]
31. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687 [TBL] [Abstract][Full Text] [Related]
32. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma. Corrêa NL; de Sá LV; de Mello RC Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670 [TBL] [Abstract][Full Text] [Related]
33. Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. Al-Qurayshi Z; Bu Ali D; Srivastav S; Kandil E Oncology; 2017; 93(2):122-126. PubMed ID: 28609768 [TBL] [Abstract][Full Text] [Related]
34. High recurrent rate of multicentric papillary thyroid carcinoma. Lin JD; Chao TC; Hsueh C; Kuo SF Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244 [TBL] [Abstract][Full Text] [Related]
36. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506 [TBL] [Abstract][Full Text] [Related]
37. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046 [TBL] [Abstract][Full Text] [Related]
38. CONCORDANCE OF PRE-OPERATIVE CLINICAL STAGE WITH PATHOLOGIC STAGE IN PATIENTS ≥45 YEARS OLD WITH WELL-DIFFERENTIATED THYROID CANCER. Calcatera NA; Lutfi W; Suman P; Suss NR; Wang CH; Prinz RA; Winchester DJ; Moo-Young TA Endocr Pract; 2018 Jan; 24(1):27-32. PubMed ID: 29144811 [TBL] [Abstract][Full Text] [Related]
39. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761 [TBL] [Abstract][Full Text] [Related]
40. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Chow SM; Yau S; Kwan CK; Poon PC; Law SC Endocr Relat Cancer; 2006 Dec; 13(4):1159-72. PubMed ID: 17158761 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]